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ABSTRACT: The Centre for Applied Genomics of the
Hospital for Sick Children and the University of Toronto
hosted the 10th Human Genome Variation (HGV)
Meeting in Toronto, Canada, in October 2008, welcoming
about 240 registrants from 34 countries. During the 3 days
of plenary workshops, keynote address, and poster
sessions, a strong cross-disciplinary trend was evident,
integrating expertise from technology and computation,
through biology and medicine, to ethics and law. Single
nucleotide polymorphisms (SNPs) as well as the larger
copy number variants (CNVs) are recognized by ever-
improving array and next-generation sequencing technol-
ogies, and the data are being incorporated into studies that
are increasingly genome-wide as well as global in scope.
A greater challenge is to convert data to information,
through databases, and to use the information for greater
understanding of human variation. In the wake of publica-
tions of the first individual genome sequences, an inaugural
public forum provided the opportunity to debate whether
we are ready for personalized medicine through direct-to-
consumer testing. The HGV meetings foster collaboration,
and fruits of the interactions from 2008 are anticipated for
the 11th annual meeting in September 2009.
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Introduction
The 10th international Human Genome Variation (HGV) Meeting
convened in October 2008, hosted by The Centre for Applied
Genomics of the Hospital for Sick Children and the University of
Toronto (Toronto, Canada). This annual gathering began in 1998 as a
small workshop focussed on ‘‘Single Nucleotide Polymorphisms
(SNPs) and Complex Genome Analysis.’’ Although the number of
delegates has expanded incrementally (to about 240 registrants
representing 34 countries) and the scope of variation described has
broadened appreciably, the conference’s interactive workshop flavor
prevails. A tone of anticipation was set with opening remarks by
Anthony Brookes and Stephen Scherer, who explained that everyone
in attendance had brought relevant science with them and that titles of
talks had been withheld from the program to encourage speakers to
present their ‘‘hottest’’ data. The 3-day format included eight plenary
sessions (Box 1) with 38 speakers, interspersed with breakout poster-
viewing sessions, a keynote address by Professor Svante Pääbo (Max
Planck Institute, Germany), and an inaugural public forum entitled
‘‘Personalized Medicine: Are We Ready?’’ (Box 2) Additional
information about the meeting is at www.tcag.ca/hgv2008, including
the full program of speakers.
In addition to the global breadth of representation, the professional
expertise of delegates covered a spectrum from genetics and genomics,
statistics and computational biology, through medical practice, human
and vertebrate biology, epidemiology, technology development, to
ethics and the law. A move to more cross-disciplinary presentations
was evident and reflected the conference’s aim to merge rather than
stratify approaches to the study of human genome variation. Notable
themes emerging were of integration (of approaches, sources of data,
and types of data) and location (in the world, and in the genome). We
discuss these, as well as social implications and other trends manifest
in this year’s proceedings, and add predictions of what is likely to
highlight research directions in this field, anticipating the 11th meeting
due to be held in Estonia in September 2009.
Integration of Data
Ten years ago, SNPs were the raison d’étre for the first
conference, and a decade of productive research has upheld the
belief in the value of these genomic representatives. At the 2006
meeting, the ‘‘new kids on the block’’ were the relatively large
structural variants, particularly copy number variants (CNVs),
and that same year the meeting title changed to ‘‘Human Genome
Variation’’ in order to acknowledge and accommodate the
enhanced spectrum of genomic variation. In 2008, there was
strong evidence that technologies—both arrays and next-genera-
tion sequencing—as well as analytical and annotation methods are
evolving to accommodate and integrate the different forms of
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variation (S. McCarroll, J. Mudge, and T. Manolio). Interspecies
comparative approaches using mouse (C. Webber) and canine
(K. Lindblad-Toh) disease models are also yielding increased
success in characterizing some genes.
A comprehensive genetic/genomic approach revealed that some
carriers of single nucleotide mutations in the TP53 gene in
families with Li-Fraumeni syndrome also have increased numbers
of genomic CNVs, which may be precursors to somatic changes
and tumor formation (D. Malkin). Genomic variation and
expression profiles were integrated to detect loci involved in
quantitative and complex traits, such as the DISC1 gene in
schizophrenia, exploring regulatory effects on its expression
(L. Almasy). SNP arrays populated with probes for CNVs are
now commercially available, and integrated data allowed the study
of segregating CNVs in HapMap samples by virtue of linkage to
SNP haplotypes (S. McCarroll). Meredith Yeager described the
need to integrate fine mapping by genomic sequencing for the
transition from genome-wide association studies (GWAS) to
direct functional studies of candidate genes. Meta-analyses, by
pooling data from related studies, provide a means to detect
variants that may be rare or have small effects (J. Hirshhorn,
M. McCarthy, and J. Rioux), and analytical methods to support
such analyses were described, such as imputing missing data
(N. Zaitlen). Esteban Parra described how admixture mapping
complements GWAS for identification of loci involved in complex
traits with population differences. Tuuli Lappalainen and Lars
Feuk each drew attention to the need for good comparative
studies of the performance of statistical approaches and
algorithms for different datasets. Finally, several presenters
described advances in building and integrating genomic databases
(Table 1), which will be key in the future development of the field.
Location—Location—Location
Genome Variation Analysis Goes Global
This year’s proceedings reflected a marked transition to more
international studies, tapping global resources for an expanded
perspective of human variation. Genomic samples from the
HapMap and Human Genome Diversity Projects (HGDP)
continue to be mined, and those from the 1000 Genomes Project
and EUropean profiles of structural and sequence VAriation of the
human genome in DISease (gEUVADIS) Project are highly
anticipated. Tuuli Lappalainen presented findings from GWAS
of four Northern European countries, focusing on natural
selection and loci with interpopulation differences, in search of
causes of human disease. Sarah Tishkoff described the step up
from targeted genotyping to genome arrays in her work to
characterize the substructure of African populations and their
relationship to the diaspora. Admixture also characterizes the
Hispanic populations of the Americas, and Estaban Parra spoke of
building a resource of ancestry-informative markers to facilitate
admixture mapping for type 2 diabetes. The Hebrew University
Genetic Resource of well-characterized Ashkenazi case-control
samples has been widely utilized for collaborative GWAS of
common disorders. Xavier Estivill outlined an ambitious initiative
in search of population-specific CNVs, using pools of HapMap
and HGDP samples and arrayCGH; results of the pilot study
demonstrate clear population clustering, with encouraging
correlation to population differences in expression phenotypes.
Developing countries have compelling reasons to invest in large-
scale genotyping projects, and Billie-Jo Hardy presented case
studies in Mexico, India, Thailand, and South Africa undertaken
to assess motivations and challenges for studying and managing
their own diversity.
Collaboration in the Global Village
Genomics is big science, and two aspects of findings from early
GWAS are driving the move to collaborative investigations. One is
that many variants relevant to traits of interest are either rare or of
small phenotypic effect, and therefore require very large sample
sizes for ascertainment. The other is that populations clearly differ
genetically, and knowledge of the breadth of such difference is
essential before applications such as medical interventions can be
considered. The differences are also tools in themselves toward
finding underlying genetic bases of human traits. Steve Scherer’s
opening comment was of ‘‘collaboration’’ and the theme prevailed.
Location in the Genome Matters
The exome has been the focus of attention for early-phase
genomics, but variation exists also between exons, near genes, and
in nongenic regions. De novo alterations (including somatic) may
disrupt the natural environment for functional elements; as
pointed out by Dalila Pinto, the number of CNVs (or SNPs for
that matter) may not be as important as where they exert their
influence. Elaine Mardis asked what important nonexonic changes
might be missed in hypothesis-driven surveys of the genome. On
this theme, several presentations considered aspects of regulation
of gene function by variable elements outside of coding sequences.
Eddie Rubin has exploited two characteristics to screen for human
enhancer elements: conservation of these nongenic sequences
among species, and their tendency to be a site for protein
coactivator binding. As many as 5,000 regulatory elements are
anticipated, along with the opportunity to investigate variation
and its impact. Steven McCarroll described an example whereby a
common deletion upstream of the IRGM gene, in complete
linkage disequilibrium with a SNP that is strongly associated with
Crohn disease, appears to be the disease-causing element through
its impact on IRGM expression and function in autophagy. David
Malkin explored the location of CNVs present in excess in TP53
mutation carriers, and found them predominantly around other
cancer-related genes, particularly DNA repair genes. Laura Almasy
outlined strategies for exploring the basic biology of upstream and
downstream effects by noncoding sequences on variable gene
Box 2. Audience response at the public forum: ‘‘Personalized
Medicine: Are We Ready?’’
‘‘I’ve been listening to why this might not be a good idea, but is there a real risk?’’
—‘‘under 30’’ law student
‘‘If a patient walked into my office with one of those print-outs, it would take me
much more than 20 minutes to look at it, which is all I have.’’
—medical student
‘‘Is it possible to turn this into something the public can actually understand?’’
—journalism student
Box 1. Plenary sessions
1. Genome Variation and Data Integration
2. Functional Variability: In Search of Plausibility
3. Comparative Genomics and Populations
4. Genome-wide Studies and Disease Susceptibility
5. Structural Variants, SNPs, and Phenotypes
6. Genome Variation: Applications and Ethics
7. Genome Variation Technologies, Tools, and Bioinformatics
8. Population Genetics and Genomics
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expression in complex traits, with a particular focus on psychiatric
endophenotypes.
Medical and Social Issues Arising
Genetic Privacy
One major issue garnering attention throughout the conference
was the impact of the recent publication [Homer et al., 2008]
describing statistical methods to discern the presence of a given
individual sample among aggregate genotype data, followed by the
action of certain funding agencies to eliminate open access to
pooled data from GWAS (S. Chanock). Discussion concerned
implications for other databases, such as the HGVbase database of
genetic association studies (A. Brookes), and the DECIPHER
database, which place individual data (albeit limited to pathological
variants) in the public realm (N. Carter). David Cox considered
whether either the extreme view expressed in connection with the
Personal Genome Project—suggesting that privacy value concerns
are outdated—or that reflected by the funders’ action, represent
broad public sentiment with respect to ‘‘trust,’’ and he advocated
more thoughtful discussion before further action. In anticipation of
such concerns, Anthony Brookes proposed a comprehensive
researcher identification system to both track and recognize
researcher activities, and enable coordinated control of access to
sensitive genotype–phenotype data (more information provided at
www.gen2phen.org). Stephen Chanock pointed out that methods
to obscure frequency data would rather defeat the purpose of their
publication for research, and advocated public discussion as a first
step toward a ‘‘genomic age.’’
Genetic Nondiscrimination
The long-awaited Genetic Information Nondiscrimination Act
(GINA) was signed into U.S. law in 2008 (D. Cox). In the context
of discussion on public representations of personal genomics, Tim
Caulfield acknowledged that opportunity for discrimination is the
biggest public concern associated with genetic disclosure, but
questioned whether such concerns are justified by experience, and,
therefore, whether GINA was necessary.
Populations and Personal Genomics
A recent discovery of diabetes susceptibility genes specific to
East Asian samples exemplifies the importance of extending
GWAS to a wider range of populations (M. McCarthy). The
developing world may not benefit from personalized therapeutics
designed primarily for populations in wealthier nations (B-J
Hardy). Tim Caulfield cited evidence that knowledge of one’s
personal genotype may have limited impact on preventive
behaviors. David Cox pointed out that use of individual genomic
variation data (such as from whole-genome sequencing) to
recommend altered clinical care will require prospective clinical
trials, and Mary Relling raised the dilemma that funding agencies
expect participants in clinical trials to be treated equally, despite
the aspiration for more personalized therapies.
For the first time, the conference program included an open
public forum, held at Victoria College of the University of Toronto.
‘‘Personalized Medicine: Are we ready?’’ brought together a diverse
panel of professionals from business, academic, and hospital
sectors to present views on the issue of direct-to-consumer genetic
testing, followed by questions from an audience of about 500.
A videocast of the session is freely available at www.tcag.ca/
hgv2008. Two companies that offer such testing were represented
(23andme and Navigenics), advocating the opportunity to provide
information to a curious public; the remaining panelists challenged
with wide-ranging concerns, particularly around the concept of
risk. When polled about whether they would undertake the test for
themselves if it were ‘‘free,’’ 1 out of 7 panelists said ‘‘yes.’’
A different age demographic and attitude from among the audience
was made evident by their questions such as in Box 2. When polled
with the same question about taking the test, about 75% raised
their hands. The moderator, Steve Scherer, noted that such forums
in various host countries would reflect issues specific to the local
health care system (which in Canada provides universal access) and
global variation in public interests, questions, and concerns.
Noted Trends and New Developments
Ascendancy of Genome-Wide Analysis
As hinted at in the 2007 conference proceedings [Estivill et al.,
2008], GWAS have yielded dramatic increases in documented
associations in the past 2 years. Teri Manolio provided an
overview from the NHGRI catalog of 180 publications (to
September 2008), and notable examples were cited by John Rioux
for inflammatory bowel disease (at 32 risk factor genes) and
autoimmune disease (68 associated risk variants), Mark McCarthy
for type 2 diabetes (at 18 associated loci), and Joel Hirschhorn for
height (43 loci) and body mass index (8 loci). Ariel Darvasi noted
that despite the impressive yield of approximately 400 novel (and
often robust) SNP associations with complex traits, these still
explain little of the genetic variation. Meredith Yeager asked, once
we find these associations, then what?, reminding the audience
that correlation does not mean causation, and fine mapping and
functional studies are essential follow-ups.
Not only SNP genotyping, but sequencing of individuals has
gone genome-wide, and the two first examples—Craig Venter and
James Watson—were described by Pauline Ng and Michael
Egholm, respectively, with additional insights from Len Penna-
chio. Elaine Mardis described applications of next-generation
sequencing in cancer diagnostics and asked whether sequencing
will soon replace microarrays. She described the first cancer
genome sequence: an acute myeloid leukemia genome and its
Table 1. Databases and Catalogs
Abbreviation Full name Website Described by
DECIPHER Database of Chromosomal Imbalance and
Phenotype Using Ensembl Resources
https://decipher.sanger.ac.uk/information N. Carter
DGV Database of Genomic Variants http://projects.tcag.ca/variation L. Feuk
GEN2PHEN Genotype to Phenotype www.gen2phen.org A. Brookes
HGVbaseG2P Human Genome Variation Association Database www.hgvbaseg2p.org A. Brookes
VEGA Vertebrate Genome Annotation Database http://vega.sanger.ac.uk/index.html J. Mudge
NHGRI GWAS catalog National Human Genome Research Institute
Genome-Wide Association Studies Catalog
www.genome.gov/gwastudies T. Manolio
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matched normal (skin) counterpart. Edison Liu speculated that
array technologies may be reaching their limits of detection, and
that pair-end sequencing strategies, which detect structural and
copy number variants, will be ready for association studies within
two years. Several noted that as generation and accumulation of
data become increasingly efficient, interpretation of such data
remains rate-limiting, but essential.
Matters of Size
Large studies reveal large numbers of variants with significant
but modest effect (J. Hirschhorn and M. McCarthy). Although
initially discouraging, these small effects may, nonetheless, draw
attention to regions and pathways of biological relevance or
identify drug targets (J. Hirschhorn and J. Rioux).
Known CNVs are becoming more numerous and smaller.
Genome-wide structural variation, first reported in 2004, has
quickly become established in the variation spectrum. Lars Feuk
described clear improvements in resolution of CNVs with tools
(including sequencing) targeted for their detection, noting that
enhanced resolution has created an apparent shift downward in size,
and that there has been an explosion in reports of variants in the
range of 100 bp to 1 kb (i.e. smaller than the operational definition
of CNV). From some 30,000 structural and copy number variants
already deposited in the Database of Genomic Variants (DGV), he
noted that 0.7% of the genome varies in copy number between
two diploid genomes, affecting a significantly larger fraction of the
genome than other types of variation (such as SNPs).
Toward Hypothesis-Free Analysis
The scope of methodologies is starting to allow more screening
approaches that detect variation without prior hypotheses,
although some studies advocate hybrid panels combining
candidate gene regions with untargeted genome-wide probes.
Three SNPs in one GWAS experiment drew attention to an
otherwise low-priority candidate gene for influence on drug
clearance in treatment of acute lymphoblastic leukemia, and this
gene is now recognized as an important metabolic determinant
with pharmacogenomic implications (M. Relling). Len Pennac-
chio commented that the classical genetics paradigm is shifting
toward ascertainment of genetic variants first, and then the
associated traits. Eventually, whole-genome sequencing will be the
means to unbiased detection of variation (M. Egholm and P. Ng).
Opportunities for Individualization
The whole-genome sequence of an individual will provide the
ultimate opportunity for specific and appropriate health inter-
ventions; however, the first such initiatives, as described in the
past 12 months, illustrate that we are far from being able to
interpret usefully the wealth of genomic variation that is
uncovered. In the meantime, studies of world population variation
(such as described above) are beginning to enhance opportunities
for more tailored approaches to health, using knowledge of group
differences. Pharmacogenomics is at the forefront of individual-
targeted care according to genotype, and examples from cancer
therapies were provided by Mary Relling.
Common and Rare Variants
Classical genetics first dealt most readily with the ‘‘sports of
nature’’—relatively rare genetic mutations of independent nature
with strong phenotypic effect. Great anticipation from the Human
Genome and HapMap Projects was for the opportunity to study
common variation and its impact on common disease; the
mushrooming accumulation of recent data from GWAS is its
outcome. Now, larger studies and meta-analyses are needed to
detect the progressively rarer residual variation, but with new
sequencing strategies for fine mapping, focus is returning to low-
frequency and rare variants (P. Ng and M. McCarthy). David Cox
noted that rare variants are more likely to yield novel therapeutics.
New Methodologies
Technical improvements abound among array technologies for
genotyping, comparative hybridization, and sequencing, with
analysis of data scrambling to keep pace with its generation.
Keynote speaker Svante Pääbo described the exciting application
of new (454) sequencing technology to ancient genomes,
particularly of Neandertal. Overcoming hurdles associated with
massive degradation and contamination, his team reported
completion of a mitochondrial sequence from the Vindija site in
August 2008, and anticipated one-fold coverage of the nuclear
sequence by the end of 2008 (15-fold coverage within a few years).
They will most likely not be able to address the really interesting
questions about genome evolution, divergence, and selection
because of small sample sizes.
The future for visualization and analysis of individual DNA
molecules was foreshadowed with two related talks. Pui Kwok
argued the need for better means to assay structural variation such
as inversion or duplication; for example, with single molecules
that retain allelic contiguity. He described efficient methods for
DNA barcoding with allele-specific or nick-labeling, to create
color-coded linear patterns suitable for automated analysis. Han
Cao then demonstrated technology to linearize DNA fragments of
any size in nanochannel arrays, with dynamic analysis of single
molecules and applications such as barcode analysis, fragment
sizing, sequencing, or protein interactions. There was some
discussion of the recent press releases from Complete Genomics
and their purported $10,000 genome sequence, and the partici-
pants were intrigued but also wanted to see the proof.
Among the computational strategies discussed were several that
related to pooling. Itsik Pe’er described resequencing of over-
lapping pools of individuals to efficiently discover rare variants
while retaining the means to identify those who are the source of
variation. In the search for population-specific CNVs, Xavier
Estivill reported pooling samples from each group to remove the
effects of individual variation, followed by arrayCGH between
pools and principal component analysis of the CNVs. Natural
pooling occurs in admixed populations, and can be exploited to
map variants for complex traits that show population differences
(E. Parra).
When data, rather than samples, are combined, such as for
meta-analysis, strategies such as imputation may be necessary
(N. Zaitlen). Rather than pooling, Gonc-alo Abecasis discussed a
strategy to increase efficiency of sequencing large numbers of
individuals by combining data from those with some shared
haplotypes in order to impute missing genotypes.
Things to Come
Steve Scherer summarized the meeting as one with many
converging themes around ‘‘Genomic Variation in a Global Village.’’
The concept seems fitting, given the transformative impact of
genetics/genomics and the Internet on society, and that the
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expression "global village" was coined by the University of Toronto
philosopher Marshall McLuhan. The 11th Human Genome
Variation meeting will likely extend this idea, with themes such
as: enumeration and influence of common CNVs; sequence data
from more individuals and more of the genome; interactions
among genes, variants, regulators, and environmental influences
described as networks; effective ways to describe and database
phenotypic variables; variation in biomolecules and their expres-
sion; as well as other topics sure to emerge in upcoming months.
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